cagrilintide clinical trial results News New in the August 14,
New in the August 14, 2025, issue of NEJM: CagrilintideSemaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) https: nej.md 444aW7f CagrilintideSemaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) https: nej.md 4ehQwLk We are all anxiously awaiting more research on the combination of cagrilintide and semaglutide (#ozempic #wegovy) which has been shown in global studies to induce very meaningful #weightloss. This study assessed the efficacy Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 eBioMedicine Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide Clinical Pharmacokinetics Springer Nature Link
Pay in 4 interest-free payments of $6.63 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5


